Procedural steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 September 2000 please refer to module 8B.  
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The Marketing Authorisation Holder (MAH), in accordance with Commission Regulation (EC) 
No.  542/95  submitted  an  application  for  a  Type  I  variation  to  change  the  name  of  the 
manufacturer  of  the  finished  medicinal  product  from  Sanofi  Winthrop,  Inc.,  USA  to  Abbott 
Laboratories, USA. The variation was accepted on 22 April 1998. 
The  MAH,  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  submitted  an 
application for a Type II variation which referred to the optimisation of the lyophilisation cycle, 
which was withdrawn on 8 July 1998. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an application for a Type II variation to amend the text of the SPC, labelling and Package 
Leaflet in the light of the data in the first PSUR. The proposed texts included revised 
information on posology, pharmacokinetics and adverse reactions, including cases of severe 
anaphylaxis. A positive opinion was adopted by the CPMP on 23 July 1998. The Commission 
decision amending the marketing authorisation was adopted on 11 November 1998. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an  application  for  a  Type  I  variation  which  referred  to  a  change  in  the  specification  of  the 
medicinal product; a notification was issued on 8 December 1998. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an  application  for  a  Type  I  variation  which  referred  to  a  change  in  the  specification  of  the 
medicinal product; a notification was issued on 8 December 1998. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an application for a Type I variation which referred to a change in the specification of the active 
substance; a notification was issued on 8 December 1998. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an application for a Type I variation which referred to a change in the specification of the active 
substance; a notification was issued on 9 October 1998. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an application for a Type I variation which referred to a change in the address of the Marketing 
Authorisation Holder; and a notification was issued on 26 October 1998.  The Commission 
Decision amending the Marketing Authorisation was adopted on 11 January 1999. 
Persuant to Article 13(2) of Council regulation (EC) No. 2309/93, as amended, the Marketing 
Authorisation  Holder  submitted  to  the  EMEA  on  27  August  1998,  the  documentation  that 
formed  the  basis  of  the  first  annual  re-assessment  of  the  benefit/risk  profile  for  BeneFIX.  A 
positive  opinion  was  issued  on  19  November  1998.  The  Commission  Decision  amending  the 
Marketing Authorisation was adopted on 29 March 1999. 
Pursuant  to  Article  10(3)  of  Council  Directive  No.  92/27/EEC,  the  Marketing  Authorisation 
Holder notified the EMEA of a change of address of the Greek representative; a notification was 
issued on 22 February 1999. The Commission Decision amending the Marketing Authorisation 
was adopted on 8 April 1999. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an application for a Type I variation which referred to a change in the specification of the active 
substance; a notification was issued on 30 June 1999. 
The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted 
an application for a Type I variation which referred to a change in specification of the finished 
product; a notification was issued on 30 June 1999. 
Persuant  to  Article  13(2)  of  Council  regulation  (EC)  No.  2309/93,  as  amended,  the  Marketing 
Authorisation  Holder  submitted  to  the  EMEA  on  2  September  1999,  the  documentation  that 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
formed the basis of the second annual re-assessment of the benefix/risk profile for BeneFIX. A 
positive  opinion  was  issued  on  18  November  1999.  The  Commission  Decision  amending  the 
Marketing Authorisation was adopted in March 2000. 
2/2 
                                                  EMEA 2005
 
 
 
 
 
 
 
 
 
 
 
 
 
